ebselen has been researched along with favipiravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, C; Barrado-Gil, L; Campillo, NE; Cuesta-Geijo, MÁ; Gil, C; Ginex, T; Maestro, I; Martinez, A; Nozal, V; Ramírez, D; Urquiza, J | 1 |
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
2 review(s) available for ebselen and favipiravir
| Article | Year |
|---|---|
COVID-19: Drug Targets and Potential Treatments.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; COVID-19 Drug Treatment; Drug Repositioning; Enzyme Inhibitors; Humans; Immunity, Innate; SARS-CoV-2 | 2020 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |